[
  {
    "ts": "2026-01-08T02:18:03+00:00",
    "headline": "Revolution Medicines (RVMD) Hits All-Time High on Buyout Buzz; Buyer Denies Talks",
    "summary": "We recently published 10 Stocks With Massive Gains; 5 at Record Highs. Revolution Medicines, Inc. (NASDAQ:RVMD) was one of the top performers on Wednesday. Revolution Medicines soared to a new all-time high on Wednesday, as investors took path from a report from The Wall Street Journal that it was set to be acquired by AbbVie […]",
    "url": "https://finance.yahoo.com/news/revolution-medicines-rvmd-hits-time-021803051.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "d41f9ce8-a0b1-359c-8449-1416338d888a",
      "content": {
        "id": "d41f9ce8-a0b1-359c-8449-1416338d888a",
        "contentType": "STORY",
        "title": "Revolution Medicines (RVMD) Hits All-Time High on Buyout Buzz; Buyer Denies Talks",
        "description": "",
        "summary": "We recently published 10 Stocks With Massive Gains; 5 at Record Highs. Revolution Medicines, Inc. (NASDAQ:RVMD) was one of the top performers on Wednesday. Revolution Medicines soared to a new all-time high on Wednesday, as investors took path from a report from The Wall Street Journal that it was set to be acquired by AbbVie […]",
        "pubDate": "2026-01-08T02:18:03Z",
        "displayTime": "2026-01-08T02:18:03Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/d13bc0eacb984711f97f75d4d5fa774a",
          "originalWidth": 768,
          "originalHeight": 474,
          "caption": "I'll Play, Says Jim Cramer About Bristol-Myers (BMY)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/mwG_K7ERKsXp5c8CgY3M_w--~B/aD00NzQ7dz03Njg7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/d13bc0eacb984711f97f75d4d5fa774a.cf.webp",
              "width": 768,
              "height": 474,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/qq.4GqsrpbstuiBHkHyOXg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/d13bc0eacb984711f97f75d4d5fa774a.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/revolution-medicines-rvmd-hits-time-021803051.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/revolution-medicines-rvmd-hits-time-021803051.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "RVMD"
            },
            {
              "symbol": "ABBV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-08T11:10:38+00:00",
    "headline": "Should Health Canada’s Eight-Week MAVIRET Approval Shape AbbVie’s (ABBV) Post-Humira Growth Story?",
    "summary": "AbbVie recently reported that Health Canada has approved MAVIRET (glecaprevir/pibrentasvir) for treating acute and chronic hepatitis C in adults and young children, making it the first and only oral eight-week pan-genotypic regimen available in Canada. This expanded indication, granted under a Priority Review based on Phase 3 data showing high efficacy in acute hepatitis C, highlights how AbbVie’s existing portfolio can still unlock new clinical and commercial opportunities without relying...",
    "url": "https://finance.yahoo.com/news/health-canada-eight-week-maviret-111038793.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "b91d8c6f-88e0-3963-b6ab-2a98a9ac07f5",
      "content": {
        "id": "b91d8c6f-88e0-3963-b6ab-2a98a9ac07f5",
        "contentType": "STORY",
        "title": "Should Health Canada’s Eight-Week MAVIRET Approval Shape AbbVie’s (ABBV) Post-Humira Growth Story?",
        "description": "",
        "summary": "AbbVie recently reported that Health Canada has approved MAVIRET (glecaprevir/pibrentasvir) for treating acute and chronic hepatitis C in adults and young children, making it the first and only oral eight-week pan-genotypic regimen available in Canada. This expanded indication, granted under a Priority Review based on Phase 3 data showing high efficacy in acute hepatitis C, highlights how AbbVie’s existing portfolio can still unlock new clinical and commercial opportunities without relying...",
        "pubDate": "2026-01-08T11:10:38Z",
        "displayTime": "2026-01-08T11:10:38Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/4451284b0632c6e74466a63400764edd",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/cbaG7tZ9A8mqrilci3AeIQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4451284b0632c6e74466a63400764edd.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/1OA9tdPdimVe1Dv1fa4MAQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/4451284b0632c6e74466a63400764edd.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/health-canada-eight-week-maviret-111038793.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/health-canada-eight-week-maviret-111038793.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-08T04:38:05+00:00",
    "headline": "1 Unpopular Stock That Deserves a Second Chance and 2 We Question",
    "summary": "Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.",
    "url": "https://finance.yahoo.com/news/1-unpopular-stock-deserves-second-043805181.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "badb6cb6-54de-3c4a-ac1f-b891a955f5b7",
      "content": {
        "id": "badb6cb6-54de-3c4a-ac1f-b891a955f5b7",
        "contentType": "STORY",
        "title": "1 Unpopular Stock That Deserves a Second Chance and 2 We Question",
        "description": "",
        "summary": "Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.",
        "pubDate": "2026-01-08T04:38:05Z",
        "displayTime": "2026-01-08T04:38:05Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/2a3b1bb7c675085376ea87403023d161",
          "originalWidth": 2400,
          "originalHeight": 1602,
          "caption": "ONTF Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/cK3PMXU9wiWEHtPm2zwLZg--~B/aD0xNjAyO3c9MjQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/stockstory_922/2a3b1bb7c675085376ea87403023d161.cf.webp",
              "width": 2400,
              "height": 1602,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/R5rqQF4VFmud1n5ZuFB22g--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/2a3b1bb7c675085376ea87403023d161.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/1-unpopular-stock-deserves-second-043805181.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/1-unpopular-stock-deserves-second-043805181.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ONTF"
            },
            {
              "symbol": "ZION"
            },
            {
              "symbol": "ABBV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-08T13:30:00+00:00",
    "headline": "Xilio Therapeutics Highlights Upcoming Milestones and Recent Corporate Updates",
    "summary": "Received $35.8 million in gross proceeds from Series B warrant exercises, including full exercise by Coastlands Capital, Frazier Life Sciences and Gilead Sciences, Inc., and extended anticipated cash runway into second quarter of 2027 Achieved development milestone for masked antibody-based program under AbbVie agreement Nominated development candidate for wholly-owned masked T cell engager program targeting CLDN18.2 Appoints Sara Bonstein as chair of board of directors WALTHAM, Mass., Jan. 08,",
    "url": "https://finance.yahoo.com/news/xilio-therapeutics-highlights-upcoming-milestones-133000534.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "58a66568-6beb-3d39-87ec-a02d6d08411e",
      "content": {
        "id": "58a66568-6beb-3d39-87ec-a02d6d08411e",
        "contentType": "STORY",
        "title": "Xilio Therapeutics Highlights Upcoming Milestones and Recent Corporate Updates",
        "description": "",
        "summary": "Received $35.8 million in gross proceeds from Series B warrant exercises, including full exercise by Coastlands Capital, Frazier Life Sciences and Gilead Sciences, Inc., and extended anticipated cash runway into second quarter of 2027 Achieved development milestone for masked antibody-based program under AbbVie agreement Nominated development candidate for wholly-owned masked T cell engager program targeting CLDN18.2 Appoints Sara Bonstein as chair of board of directors WALTHAM, Mass., Jan. 08,",
        "pubDate": "2026-01-08T13:30:00Z",
        "displayTime": "2026-01-08T13:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/790a3773663b9c214f4e9c03501ad13e",
          "originalWidth": 462,
          "originalHeight": 289,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/5DNoESZWUKyrVSc2qDeKJg--~B/aD0yODk7dz00NjI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/790a3773663b9c214f4e9c03501ad13e.cf.webp",
              "width": 462,
              "height": 289,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/IdUhLi0fZ6WKrAPs890dfw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/790a3773663b9c214f4e9c03501ad13e.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/xilio-therapeutics-highlights-upcoming-milestones-133000534.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/xilio-therapeutics-highlights-upcoming-milestones-133000534.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "XLO"
            },
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "GILD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-08T12:38:00+00:00",
    "headline": "AbbVie Denies It’s in Talks to Buy Revolution Medicines. Both Stocks Are Falling.",
    "summary": "AbbVie  on Thursday denied that it is in talks to buy cancer-drug biotech Revolution Medicines, sending both stocks lower ahead of the opening bell.  “AbbVie is not in talks to acquire Revolution Medicines,” an AbbVie spokesperson told Barron’s. The Wall Street Journal reported on Wednesday that the two companies were close to a deal, citing people familiar with the matter.  AbbVie stock fell 1.5% to $229.98 ahead of Thursday’s opening bell, having jumped 4.2% the previous session following The Journal’s report.",
    "url": "https://www.barrons.com/articles/abbvie-stock-revolution-medicines-deal-60137788?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "e068a25c-ca2d-361c-87d7-3d16d93080a7",
      "content": {
        "id": "e068a25c-ca2d-361c-87d7-3d16d93080a7",
        "contentType": "STORY",
        "title": "AbbVie Denies It’s in Talks to Buy Revolution Medicines. Both Stocks Are Falling.",
        "description": "",
        "summary": "AbbVie  on Thursday denied that it is in talks to buy cancer-drug biotech Revolution Medicines, sending both stocks lower ahead of the opening bell.  “AbbVie is not in talks to acquire Revolution Medicines,” an AbbVie spokesperson told Barron’s. The Wall Street Journal reported on Wednesday that the two companies were close to a deal, citing people familiar with the matter.  AbbVie stock fell 1.5% to $229.98 ahead of Thursday’s opening bell, having jumped 4.2% the previous session following The Journal’s report.",
        "pubDate": "2026-01-08T12:38:00Z",
        "displayTime": "2026-01-08T12:38:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/e068a25c-ca2d-361c-87d7-3d16d93080a7/abbvie-denies-it%E2%80%99s-in-talks.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/766f5fc9d8b0980890648d7ab98b35e4",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/FP0W4_kiWUk9rWw.Y.wylQ--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/766f5fc9d8b0980890648d7ab98b35e4.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/uzwmfEZQlsFuUzI3Dy6_Ug--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/766f5fc9d8b0980890648d7ab98b35e4.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/abbvie-stock-revolution-medicines-deal-60137788?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "RVMD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-08T11:54:00+00:00",
    "headline": "These Stocks Are Moving the Most Today: Northrop, Lockheed, Alphabet, Revolution Medicines, AbbVie, Costco, and More",
    "summary": "Northrop Grumman, Lockheed Martin, and RTX rally after President Donald Trump says he would hike the defense budget to $1.5 trillion next year.",
    "url": "https://www.barrons.com/articles/stock-movers-075503a6?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "35aeb204-a9fa-30d0-a073-01d136dfb3e6",
      "content": {
        "id": "35aeb204-a9fa-30d0-a073-01d136dfb3e6",
        "contentType": "STORY",
        "title": "These Stocks Are Moving the Most Today: Northrop, Lockheed, Alphabet, Revolution Medicines, AbbVie, Costco, and More",
        "description": "",
        "summary": "Northrop Grumman, Lockheed Martin, and RTX rally after President Donald Trump says he would hike the defense budget to $1.5 trillion next year.",
        "pubDate": "2026-01-08T11:54:00Z",
        "displayTime": "2026-01-08T11:54:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/35aeb204-a9fa-30d0-a073-01d136dfb3e6/these-stocks-are-moving-the.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/bd5b1245cc4c6c856a1d187e16098100",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/EmCQbmLQKD_TcTMCYlzpQg--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/bd5b1245cc4c6c856a1d187e16098100.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/RhNsBgx0oQKKQb1zB5mlxg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/bd5b1245cc4c6c856a1d187e16098100.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/stock-movers-075503a6?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LMT"
            },
            {
              "symbol": "AAPL"
            },
            {
              "symbol": "NOC"
            },
            {
              "symbol": "RTX"
            },
            {
              "symbol": "GD"
            },
            {
              "symbol": "HII"
            },
            {
              "symbol": "GOOG"
            },
            {
              "symbol": "RVMD"
            },
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "COST"
            },
            {
              "symbol": "LHX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]